MARKET

GKOS

GKOS

Glaukos Corp
NYSE
119.82
+2.17
+1.84%
After Hours: 119.82 0 0.00% 16:46 07/26 EDT
OPEN
119.16
PREV CLOSE
117.65
HIGH
120.15
LOW
117.45
VOLUME
617.62K
TURNOVER
0
52 WEEK HIGH
126.96
52 WEEK LOW
59.22
MARKET CAP
6.54B
P/E (TTM)
-41.5868
1D
5D
1M
3M
1Y
5Y
1D
Glaukos Reaches Analyst Target Price
NASDAQ · 2d ago
Glaukos (GKOS) Gains 51.9% YTD: What's Driving the Stock?
NASDAQ · 4d ago
Healthcare 2024 Second Half Outlook
Seeking Alpha · 4d ago
Weekly Report: what happened at GKOS last week (0715-0719)?
Weekly Report · 4d ago
Glaukos Corporation's (NYSE:GKOS) Popularity With Investors Is Clear
Glaukos Corporation's price-to-sales ratio of 20.8x is higher than the Medical Equipment industry average. The company's revenue growth is superior to most other companies in the industry. Glaukos' P/S ratio is high on the merit of its strong future revenues. It is expected to grow revenue by 23% per year over the next three years.
Simply Wall St · 07/18 11:02
Will WATCHMAN Sales Aid Boston Scientific's (BSX) Q2 Earnings?
NASDAQ · 07/16 15:23
Glaukos Price Target Raised to $141.00/Share From $125.00 by Truist Securities
Dow Jones · 07/16 13:49
Glaukos Is Maintained at Buy by Truist Securities
Dow Jones · 07/16 13:49
More
About GKOS
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.

Webull offers Glaukos Corp stock information, including NYSE: GKOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GKOS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GKOS stock methods without spending real money on the virtual paper trading platform.